Trillium Therapeutics Inc (TRIL)

MATERIALS: CHEMICALS
SIC:

96 SKYWAY AVENUE TORONTO, ONTARIO, CANADA M9W 4Y9

Stem Cell Therapeutics Corp. engages in the development and commercialization of stem cell-based therapies for cell therapy and regenerative medicine in Canada. The company develops a drug-based therapy that utilizes drugs to stimulate a patients own resident adult stem cells, as well as to repair neurological functions lost due to conditions, such as stroke; multiple sclerosis; or traumatic brain injury.

Data as of 2020-05-30
Market Cap565.7 Million Shares Outstanding82.683 Million Avg 30-day Volume2.413 Million
P/E Ratio Dividend Yield EPS-1.87
Price/Sales3508.37 Price cash flow ratio Price free cash flow ratio-26.8
Book Value-0.12 Price to Tangible Book-83.7 Alpha0.04
Short Interest Ratio % Short Interest to Float R-squared0.034392
BETA2.19748 52-week High/Low7.97 / 0.2405 Stddev0.506554
View SEC Filings from TRIL instead.

Funds Holding TRIL (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding TRIL BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5
No current insider transactions

Elevate your investments